23andMe Investor Presentation Deck

Inhibition of CD200R1 has the potential to address resistance to anti-PD1 therapies Blocking the CD200R1 pathway enhanced IFNy production from SEB-stimulated PBMCs compared to isotype control and anti-PD1 in the majority of samples tested Interferon-y Fold Change Relative to Control 2 *L Endometrial 1 Ovarian 1 Endometrial 2 Lung Melanoma Pancreatic Endometrial 3 PBMCs from each respective patient were incubated with 100 nM of 23ME-00610, anti-PD-1, or isotype control. Cells were stimulated with SEB. IFNy levels were determined by enzyme-linked immunosorbent assay. Mean biologic triplicates were normalized to isotype control. *P <0.05. 23ME '610 Isotype Control anti-PD1 Prostate Colorectal Copyright © 2022 23and Me, Inc. PBMC, peripheral blood mononuclear cell; PD-1, programmed death-1; SEB, staphylococcal enterotoxin B. 23andMe 43

View entire presentation